Andrew Spence, PA
Physician Assistant · Quinton, VANPI 1619511854
Payments from drug & device makers
Across 354 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$924
- Novo Nordisk$912
- Pfizer$832
- AstraZeneca$394
- GSK$326
- Shield Therapeutics Inc$326
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,436100%
- Education$80%
- Entertainment$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 84 | $924 |
| Novo Nordisk | 62 | $912 |
| Pfizer | 66 | $832 |
| AstraZeneca(2 entities) | 14 | $394 |
| GSK | 22 | $326 |
| Shield Therapeutics Inc | 8 | $326 |
| Bayer | 18 | $281 |
| Lilly USA, LLC | 15 | $280 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $171 |
| Otsuka America Pharmaceutical, Inc. | 5 | $114 |
| Dexcom, Inc. | 6 | $109 |
| Boehringer Ingelheim | 6 | $107 |
| Axsome Therapeutics, Inc. | 5 | $92 |
| Novartis | 4 | $60 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 2 | $49 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Edwards Lifesciences | 2 | $36 |
| Merck | 1 | $32 |
| Johnson & Johnson | 2 | $29 |
| Boston Scientific | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Phadia US Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $20 |
| Exact Sciences | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Philips North America LLC | 1 | $19 |
| Abbott | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Amgen | 1 | $15 |
| Optos, Inc. | 1 | $15 |
| Ardelyx, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,459 in reported general payments places this provider in the 90th percentile of 3,376 physician assistant providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 108 | $129,881 |
| MounjaroTirzepatide | 68 | $67,282 |
| FarxigaDapagliflozin Propanediol | 46 | $61,710 |
| JardianceEmpagliflozin | 50 | $53,961 |
| EliquisApixaban | 43 | $38,649 |
| VraylarCariprazine Hcl | 24 | $38,131 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 18 | $27,692 |
| RybelsusSemaglutide | 11 | $24,766 |
| TrulicityDulaglutide | 16 | $24,398 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $19,342 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $19,224 |
| XareltoRivaroxaban | 11 | $16,704 |
| JanuviaSitagliptin Phosphate | 16 | $13,247 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $6,002 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $912 | $154,648119 claims |
| Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr | $107 | $100,87684 claims |
| Lilly USA, LLCMounjaro, Trulicity | $280 | $91,67984 claims |
| AstraZenecaFarxiga | $394 | $61,71046 claims |
| AbbVieVraylar, Synthroid | $924 | $39,56449 claims |
| PfizerEliquis | $832 | $38,64943 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $326 | $25,11725 claims |
| Johnson & JohnsonXarelto | $29 | $16,70411 claims |
| MerckJanuvia | $32 | $13,24716 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $1,657155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,376 physician assistant providers in Virginia.
Other physician assistant in Quinton
- John DalessandroSalem$160K
- Jalal AlghabraFredericksburg$119K
- Jamie GiovanelliVirginia Beach$118K
- John CarterStaunton$90K
- Melissa AlcoxNorfolk$73K
- Lindsay TomReston$71K
- Robert HigginsonRichmond$66K
- Jameka McElroy-BrooklynArlington$65K
- Hillary HartungNorfolk$62K
- Juliette BeristainVirginia Beach$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.